---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Heterogeneity of treatment effect"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Heterogeneity of treatment effect. Topics: REVEAL Part A: response across age, disease severity, and genotype; REVEAL Part A: response by dose cohort; Published review: dose response in the first REVEAL cohorts; MECP2 variant: genotype coverage of the miniMECP2 transgene; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### REVEAL Part A: response across age, disease severity, and genotype

> “Patients were 6‒21 YOA, with diverse clinical histories, broad disease severity (CGI-S 4 to 6), and varied MECP2 mutations to reflect a real-world population”
> “16 DMs in pediatric (n=6) and 15 DMs in adolescent/adult (n=6) patients support the broad treatment potential of TSHA-102”
> “Broad functional impact consistently demonstrated across core disease domains post-TSHA-102 regardless of age, disease severity or genotype”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-2.2.2.3-2"></a>

### REVEAL Part A: response by dose cohort

> “75% of patients in the high dose cohort achieved ≥2 milestones post-TSHA-102”
> “Average score ≥18 months post-TSHA-102: -15.7 in high dose cohort -7.8 in low dose cohort”
> “TSHA-102 demonstrated early global improvement, with dose-dependent effects that deepened over time in CGI-I”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-2.2.2.3-3"></a>

### Published review: dose response in the first REVEAL cohorts

> “A clear dose–response relationship was observed: participants receiving 1 × 1015 vg demonstrated faster and more pronounced functional gains than those receiving 5.7 × 1014 vg.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.3-4"></a>

### MECP2 variant: genotype coverage of the miniMECP2 transgene

> “By delivering the essential MBD and NID functional domains, TSHA-102 provides a genotype-agnostic approach that encompasses the molecular defects found in over 95% of the RTT population, including the eight most common recurrent mutations and nearly all pathogenic missense variants.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.3-5"></a>

### MECP2 variant and X-chromosome inactivation: sources of variation in disease severity

> “Thus, we have confirmed that MECP2 mutation type is a strong predictor of disease severity. However, clinical severity continues to become progressively worse with advancing age regardless of initial severity.”

Source: [Cuddapah et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4403764/)

> “Because the MECP2 gene is subject to X‐chromosome inactivation (XCI), factors including MECP2 genotypic variation, tissue differences in XCI, and skewing of XCI all likely contribute to the clinical severity of individuals with RTT.”

Source: [Fang et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9034674/)

<a id="topic-2.2.2.3-6"></a>

### Age at treatment: developmental window

> “Nonetheless, several considerations favor earlier intervention: the first 2–3 years of life represent critical windows of synaptogenesis and circuit formation; prolonged MeCP2 deficiency may lead to structural neuronal and glial changes that become harder to reverse; and treating before or during early regression could prevent milestone loss rather than requiring later recovery (83, 84).”
> “Ultimately, a stratified approach may emerge in which early treatment maximizes developmental potential while older individuals are treated to achieve meaningful functional gains.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

<a id="topic-2.2.2.3-7"></a>

### Age at treatment: spontaneous milestone gain before 6 years of age in natural history

> “Before 6 years of age, milestone gain, loss, and regain were more variable and less predictable, with spontaneous first-time gain for a single milestone as high as 97%; inclusion of younger participants without explicit age accounting could increase background spontaneous gain and thereby increase type I error”
> “No consistent significant predictors of gain/regain were identified across the 28 milestones”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

<a id="topic-2.2.2.3-8"></a>

### Children aged 2 to less than 6 years: efficacy extrapolated from older participants

> “A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
